High interest for long-acting injectable PrEP among pregnant women taking daily oral PrEP in Kisumu and Siaya, Kenya

Tessa Concepcion
University of Washington
June 13, 2023
Funding acknowledgements

R01NR019220

F31HD112236
>50% discontinue PrEP within 30 days

mWACCh-PrEP

- Ongoing RCT at 5 antenatal clinics in Kisumu and Siaya, Kenya (NCT04472884)
- Eligibility
  - HIV-negative
  - ≥18 years
  - 24-32 weeks gestation
  - High risk of HIV (HIV risk score ≥6, ~ 8.9 HIV infections per 100 person-years)
  - Newly initiating PrEP
- Followed through 9 months postpartum
Methods

Data on long-acting PrEP preferences collected starting November 2022

At each study visit
- Behavioral characteristics
- Social factors
- PrEP use
- Long-acting PrEP interest and implementation factors

Multinomial generalized estimating equation
Baseline characteristics

- 231 women contributed
- 495 visits in pregnancy
- 24 years median age at enrollment
- 87.0% had a partner with unknown HIV status
- 26 weeks median gestational age at enrollment
- 3.9% had a partner living with HIV
- 36.4% primigravida
LA-PrEP interest among pregnant women

<table>
<thead>
<tr>
<th>ANC visit</th>
<th>Total N</th>
<th>Gestational age (weeks)</th>
<th>Time on PrEP (days)*</th>
<th>Discontinuing PrEP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st ANC follow-up</td>
<td>169</td>
<td>30.9 (2.8)</td>
<td>28.5 (5.8)</td>
<td>14 (8.3)</td>
</tr>
<tr>
<td>2nd ANC follow-up</td>
<td>163</td>
<td>34.4 (2.5)</td>
<td>56.7 (7.4)</td>
<td>26 (16)</td>
</tr>
<tr>
<td>3rd ANC follow-up</td>
<td>111</td>
<td>37.1 (1.9)</td>
<td>82.6 (9.9)</td>
<td>19 (17.1)</td>
</tr>
<tr>
<td>4th ANC follow-up</td>
<td>52</td>
<td>39.9 (1.9)</td>
<td>104.5 (13.9)</td>
<td>10 (19.2)</td>
</tr>
</tbody>
</table>

Mean (SD) for Total N, Mean (SD) for Time on PrEP (days), N (%) for Discontinuing PrEP

**Interest in LA-injectable PrEP**
- Very interested
- Interested
- Slightly interested
- Not all interested

*Excluding participants who discontinued PrEP
LA-PrEP interest among pregnant women

- **Long-acting injectable PrEP (with shots every 2 months)**:
  - 1st ANC visit: 88%
  - 2nd ANC visit: 84%
  - 3rd ANC visit: 90%
  - 4th ANC visit: 85%

- **Daily oral PrEP (with refills every 3 months)**:
  - 1st ANC visit: 5%
  - 2nd ANC visit: 7%
  - 3rd ANC visit: 3%
  - 4th ANC visit: 6%

- **Vaginal ring (with monthly replacements)**:
  - 1st ANC visit: 1%
  - 2nd ANC visit: 1%
  - 3rd ANC visit: 7%
  - 4th ANC visit: 7%

- **Neither**:
  - 1st ANC visit: 1%
  - 2nd ANC visit: 1%
  - 3rd ANC visit: 1%
  - 4th ANC visit: 6%

- **Unsure**:
  - 1st ANC visit: 1%
  - 2nd ANC visit: 3%
  - 3rd ANC visit: 2%

**Preferred PrEP form**

ANC visit: 1st ANC visit, 2nd ANC visit, 3rd ANC visit, 4th ANC visit
LA-PrEP interest among pregnant women

Willingness to pay for a LA-injectable PrEP (KES)

LA-PrEP interest: Slightly interested, Interested, Very interested
LA-PrEP interest among pregnant women

Preferred collection location for LA-PrEP

<table>
<thead>
<tr>
<th>Location</th>
<th>1st ANC visit</th>
<th>2nd ANC visit</th>
<th>3rd ANC visit</th>
<th>4th ANC visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare clinic</td>
<td>85%</td>
<td>82%</td>
<td>87%</td>
<td>81%</td>
</tr>
<tr>
<td>Family planning clinic</td>
<td>1%</td>
<td>4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retail pharmacy</td>
<td>1%</td>
<td>1%</td>
<td>4%</td>
<td></td>
</tr>
</tbody>
</table>

ANC visit
### PrEP use throughout pregnancy

<table>
<thead>
<tr>
<th></th>
<th>1st ANC follow-up</th>
<th>2nd ANC follow-up</th>
<th>3rd ANC follow-up</th>
<th>4th ANC follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gestational age (weeks)</strong></td>
<td>30.9 (2.8)</td>
<td>34.4 (2.5)</td>
<td>37.1 (1.9)</td>
<td>39.9 (1.9)</td>
</tr>
<tr>
<td><strong>Time on PrEP (days)</strong></td>
<td>28.5 (5.8)</td>
<td>56.7 (7.4)</td>
<td>82.6 (9.9)</td>
<td>104.5 (13.9)</td>
</tr>
<tr>
<td><strong>Discontinuing PrEP</strong></td>
<td>14 (8.3)</td>
<td>26 (16)</td>
<td>19 (17.1)</td>
<td>10 (19.2)</td>
</tr>
<tr>
<td><strong>Missed any PrEP</strong></td>
<td>84 (49.7)</td>
<td>57 (35.0)</td>
<td>44 (39.6)</td>
<td>30 (38.5)</td>
</tr>
</tbody>
</table>

**Mean (SD)**
Factors associated with LA-PrEP interest

Level of interest
- Very interested
- Interested
- Slightly interested
- Not at all interested

Predictors of interest
- Behavioral characteristics
- Social characteristics
- PrEP use

Measured at up to 4 visits per participant during pregnancy
Factors associated with increased interest in LA-PrEP
Implications and next steps

High interest in long-acting injectable PrEP among pregnant women

Alternative PrEP methods may be appropriate for pregnant women with suboptimal adherence to daily oral PrEP

- Preferences for PrEP formulations
- Identify early process indicators for implementing long-acting PrEP into MCH systems
Thank you

<table>
<thead>
<tr>
<th>Study team</th>
<th>Contributors</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kinuthia</td>
<td>Study nurses</td>
</tr>
<tr>
<td>Felix Abuna</td>
<td>Participants</td>
</tr>
<tr>
<td>Eunita Akim</td>
<td></td>
</tr>
<tr>
<td>Julia Dettinger</td>
<td></td>
</tr>
<tr>
<td>Laurén Gómez</td>
<td></td>
</tr>
<tr>
<td>Emma Mukenyi</td>
<td></td>
</tr>
<tr>
<td>Nancy Ngumbau</td>
<td></td>
</tr>
<tr>
<td>Jerusha Nyabiage</td>
<td></td>
</tr>
<tr>
<td>Ben Ochieng</td>
<td></td>
</tr>
<tr>
<td>Salphine Watoyi</td>
<td></td>
</tr>
<tr>
<td>Jillian Pintye</td>
<td></td>
</tr>
</tbody>
</table>

15